Abstract 558P
Background
In Asian populations, there is a lack of substantial real-world data for brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor for patients with NSCLC. The aim of this study was to analyze real-world brigatinib treatment outcomes and dosing patterns in patients with ALK+ NSCLC who had received prior crizotinib in South Korea.
Methods
This retrospective, non-interventional cohort study used Health Insurance and Review Assessment claims data. The study included patients (>20 years old) who initiated brigatinib from 19 April 2019 to 31 March 2021 and who received crizotinib before brigatinib. We assessed patients' characteristics, treatment discontinuation, dose reduction, overall survival (OS) and adherence. Time to treatment discontinuation (TTD), time to dose reduction and OS were analyzed using Kaplan-Meier estimates. Patients whose proportion of days covered (PDC) was ≥0.8 were defined as treatment adherent.
Results
A total of 174 crizotinib-refractory patients (56.9% male; 27.1% brain metastasis history) with ALK+ NSCLC were included in the analysis (median [range] follow-up: 18 [0–34] months); the median treatment duration of prior crizotinib was 17 months. For brigatinib as second-line treatment, the median TTD was 25 months (95% CI:15.2–NE). 1- and 2-year treatment continuation rates were 63.2% and 51.5%, respectively. Median OS was not reached during the study period. The 2-year OS rate was 68.7%. 88.5% of patients reached full-dose brigatinib (180 mg/day) during treatment duration. The probability of continuing brigatinib at full dose (180 mg/day) or at peak dose (<180 mg/day) was 79.7% and 75.6% at 1 and 2 years, respectively. Overall, 93.1% of patients were adherent to brigatinib during treatment. The median PDC of brigatinib treatment was 0.98.
Conclusions
This is the first nationwide, real-world study of brigatinib treatment in a large cohort of crizotinib-refractory ALK+ NSCLC patients in South Korea. In this study, brigatinib demonstrated a longer treatment duration than in published clinical trials, as well as a favorable 2-year OS rate and high adherence. Second-line brigatinib treatment is of benefit in a real-world setting in South Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
J.H. Nam, S.H. Kwon: Financial Interests, Personal and Institutional, Research Grant: Takeda. B. Kim, S. Ha: Financial Interests, Personal, Full or part-time Employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract